Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aileron Therapeutics Inc (ALRN)

Aileron Therapeutics Inc (ALRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,427
  • Shares Outstanding, K 90,824
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,160 K
  • 60-Month Beta 2.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.53
Trade ALRN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings -0.09 on 05/05/22
  • Next Earnings Date 08/17/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.09
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1310 +65.80%
on 08/02/22
0.2549 -14.79%
on 07/19/22
-0.0066 (-2.95%)
since 07/15/22
3-Month
0.1310 +65.80%
on 08/02/22
0.4800 -54.75%
on 06/03/22
-0.1583 (-42.16%)
since 05/16/22
52-Week
0.1310 +65.80%
on 08/02/22
1.2700 -82.90%
on 09/10/21
-0.8128 (-78.91%)
since 08/16/21

Most Recent Stories

More News
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced...

ALRN : 0.2173 (+1.59%)
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...

ALRN : 0.2173 (+1.59%)
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924...

ALRN : 0.2173 (+1.59%)
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicitiesTrial...

ALRN : 0.2173 (+1.59%)
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer...

ALRN : 0.2173 (+1.59%)
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia)New non-clinical data demonstrate...

ALRN : 0.2173 (+1.59%)
Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in...

ALRN : 0.2173 (+1.59%)
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?

Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.

ALRN : 0.2173 (+1.59%)
FNA : 19.28 (-5.58%)
Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year?

Here is how Aileron Therapeutics, Inc. (ALRN) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

ALRN : 0.2173 (+1.59%)
BDX : 268.68 (+0.70%)
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated...

ALRN : 0.2173 (+1.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers...

See More

Key Turning Points

3rd Resistance Point 0.2443
2nd Resistance Point 0.2312
1st Resistance Point 0.2226
Last Price 0.2173
1st Support Level 0.2009
2nd Support Level 0.1878
3rd Support Level 0.1792

See More

52-Week High 1.2700
Fibonacci 61.8% 0.8349
Fibonacci 50% 0.7005
Fibonacci 38.2% 0.5661
Last Price 0.2173
52-Week Low 0.1310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar